A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

This is a pilot clinical trial investigating the addition of haploidentical natural killer cell infusion to autologous stem cell transplantation. This intervention will be evaluated in children with high-risk solid tumors for whom autologous transplantation is indicated. Natural killer cells from a haploidentical family member will be given after high dose chemotherapy and positively selected autologous stem cells. In patients with neuroblastoma, the anti-GD2 antibody hu14.18K322A will also be given. The effect on normal hematopoietic cell recovery will be evaluated and survival of children treated with this approach will be determined.
The investigators expect to enroll 36 participants. Haploidentical family members (donors) will also be recruited to provide natural killer cells.

开始日期2014-10-10

申办/合作机构

St. Jude Children's Research Hospital, Inc.

NCT01857934

/ Active, not recruiting临床2期IIT

Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk Neuroblastoma

Neuroblastoma is the most common extracranial solid tumor in childhood, with nearly 50% of patients presenting with widespread metastatic disease. The current treatment for this group of high-risk patients includes intensive multi-agent chemotherapy (induction) followed by myeloablative therapy with stem-cell rescue (consolidation) and then treatment of minimal residual disease (MRD) with isotretinoin. Recently a new standard of care was established by enhancing the treatment of MRD with the addition of a monoclonal antibody (ch14.18) which targets a tumor-associated antigen, the disialoganglioside GD2, which is uniformly expressed by neuroblasts. Despite improvement in 2-year event-free survival (EFS) of 20%, more than one-third of children with high-risk neuroblastoma (HR defined in) still cannot be cured by this approach. Therefore, novel therapeutic approaches are needed for this subset of patients. This study will be a pilot Phase II study of a unique anti-disialoganglioside (anti-GD2) monoclonal antibody (mAb) called hu14.18K322A, given with induction chemotherapy.
PRIMARY OBJECTIVE:
* To study the efficacy [response: complete remission + partial remission (CR+PR)] to two initial courses of cyclophosphamide and topotecan combined with hu14.18K322A (4 doses/course followed by GM-CSF) in previously untreated children with high-risk neuroblastoma.
* To estimate the event-free survival of patients with newly diagnosed high-risk neuroblastoma treated with the addition of hu14.18K322A to treatment.
SECONDARY OBJECTIVES:
* To study the feasibility of delivering hu14.18K322A to 6 cycles induction chemotherapy and describe the antitumor activity (CR+PR) of this 6 course induction therapy.
* To estimate local control and pattern of failure associated with focal intensity modulated or proton beam radiation therapy dose delivery in high-risk abdominal neuroblastoma.
* To describe the tolerability of four doses of hu14.18K322A with allogeneic natural killer (NK) cells from an acceptable parent, in the immediate post-transplant period [day +2 - +5 after peripheral blood stem cell (PBSC) infusion] in consenting participants.
* To describe the tolerability of hu14.18K322A with interleukin-2 and GM-CSF as treatment for minimal residual disease (MRD).

开始日期2013-07-05

申办/合作机构

St. Jude Children's Research Hospital, Inc.

[+2]

NCT01576692

/ Completed临床1期IIT

A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) With and Without Natural Killer Cells to Chemotherapy in Children and Adolescents With Recurrent/Refractory Neuroblastoma

This is a safety / feasibility trial evaluating the combination of a humanized anti-GD2 antibody (HU14.18K322A) manufactured at the Children's GMP, LLC at St. Jude with allogeneic natural killer (NK) cells and standard chemotherapy in children with relapsed or refractory neuroblastoma.

开始日期2012-04-01

申办/合作机构

St. Jude Children's Research Hospital, Inc.

[+1]

100 项与 Hu14.18K322A 相关的临床结果

登录后查看更多信息

100 项与 Hu14.18K322A 相关的转化医学

登录后查看更多信息

100 项与 Hu14.18K322A 相关的专利（医药）

登录后查看更多信息

项与 Hu14.18K322A 相关的文献（医药）

2025-04-01·Journal of Pediatric Hematology/Oncology

PHOX2B-associated Congenital Central Hypoventilation Syndrome Revealed Upon Treatment With Dinutuximab-beta

Article

作者: Couque, Nathalie ; Jouglar, Emmanuel ; Schleiermacher, Gudrun ; Aerts, Isabelle ; Valteau-Couanet, Dominique ; Chupin, Alix ; Masliah-Planchon, Julien ; Bouchoucha, Yassine ; Simaga, Fatoumata ; Philippe-Chomette, Pascale ; Mayer, Sophie ; Masserot, Caroline ; Bourdeaut, Franck ; Benkaddouss, Sakina ; Gauthier-Villars, Marion ; Bokov, Plamen ; Dudoignon, Benjamin

Alterations of PHOX2B function is associated with a wide range of diseases, including congenital central hypoventilation syndrome (CCHS) and neural crest-derived tumors, from low-grade (ganglioneuromas) to malignant forms (neuroblastomas). We report a case bearing a novel nonpolyalanine repeat PHOX2B pathogenic variant presenting both as high-risk neuroblastoma and late-onset CCHS. CCHS was revealed upon severe respiratory decompensation while the patient was administered the anti-GD2 antibody dinutuximab-beta, as part of neuroblastoma treatment. From this experience, we make propositions for the management of patients with high-risk neuroblastoma and a constitutional pathogenic variant of PHOX2B.

2025-03-01·Supportive Care in Cancer

Strategies to manage the adverse effects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review

Review

作者: Conte, Massimo ; De Ioris, Maria Antonietta ; Amoroso, Loredana ; Luksch, Roberto ; De Leonardis, Francesco ; Fagioli, Franca ; Tondo, Annalisa ; Badino, Clara ; Viscardi, Elisabetta ; Di Cataldo, Andrea

PURPOSEPatients with high-risk neuroblastoma (HR NB) frequently present with metastases in the bone marrow and bone. Approximately 15% of these patients are refractory to induction therapy, and 50% relapse. Dinutuximab beta is an anti-GD2 monoclonal antibody approved in Europe for maintenance therapy of pediatric patients with HR NB. Immunotherapy with anti-GD2 antibodies improves the survival of children with HR NB and relapsed or refractory disease. It is associated with adverse events, such as pain, fever, allergic reactions, capillary leak syndrome, and diarrhea. This manuscript aims to propose a practical guide in support and prevention treatment of adverse events.METHODSMEDLINE was searched using the terms "GD2," "ch14.18/CHO," "anti-GD2 antibody," "dinutuximab beta," and "neuroblastoma." The experts reappraised available evidence discussing different clinical Italian experiences.RESULTSNeuropathic pain is the main toxicity associated with dinutuximab beta and can be prevented with analgesics, including intravenous opioids and gabapentin by mouth. The intensity of the supportive treatment decreases from course to course.CONCLUSIONIn the experience of the authors, adverse events associated with dinutuximab beta may be prevented and managed in experienced centers. The supportive therapy may be reduced after the first cycle to improve the quality of life.

2024-09-01·Radiotherapy and Oncology

Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field

Article

作者: Shaaban, Sherif G ; Bagatell, Rochelle ; Liu, Kevin X ; Yock, Torunn I ; Friedmann, Alison M ; Chen, Jie Jane ; Braunstein, Steve E ; Shusterman, Suzanne ; Catalano, Paul J ; Vo, Kieuhoa T ; Ioakeim-Ioannidou, Myrsini ; Marcus, Karen J ; Diller, Lisa R ; Hill-Kayser, Christine E ; Dusenbery, Kathryn E ; Elhalawani, Hesham ; Haas-Kogan, Daphne A ; Lerman, Benjamin J ; MacDonald, Shannon M ; Huang, Mary S ; Mattei, Peter ; DuBois, Steven G ; Vu, Lan ; Shamberger, Robert C ; Terezakis, Stephanie A

BACKGROUNDPrognosis for patients with high-risk neuroblastoma (HR-NBL) is guarded despite aggressive therapy, and few studies have characterized outcomes after radiotherapy in relation to radiation treatment fields.METHODSMulti-institutional retrospective cohort of 293 patients with HR-NBL who received autologous stem cell transplant (ASCT) and EBRT between 1997-2021. LRR was defined as recurrence at the primary site or within one nodal echelon beyond disease present at diagnosis. Follow-up was defined from the end of EBRT. Event-free survival (EFS) and OS were analyzed by Kaplan-Meier method. Cumulative incidence of locoregional progression (CILP) was analyzed using competing risks of distant-only relapse and death with Gray's test.RESULTSMedian follow-up was 7.0 years (range: 0.01-22.4). Five-year CILP, EFS, and OS were 11.9 %, 65.2 %, and 77.5 %, respectively. Of the 31 patients with LRR and imaging review, 15 (48.4 %) had in-field recurrences (>12 Gy), 6 (19.4 %) had marginal failures (≤12 Gy), and 10 (32.3 %) had both in-field and marginal recurrences. No patients receiving total body irradiation (12 Gy) experienced marginal-only failures (p = 0.069). On multivariable analyses, MYCN amplification had higher risk of LRR (HR: 2.42, 95 % CI: 1.06-5.50, p = 0.035) and post-consolidation isotretinoin and anti-GD2 antibody therapy (HR: 0.42, 95 % CI: 0.19-0.94, p = 0.035) had lower risk of LRR.CONCLUSIONSDespite EBRT, LRR remains a contributor to treatment failure in HR-NBL with approximately half of LRRs including a component of marginal failure. Future prospective studies are needed to explore whether radiation fields and doses should be defined based on molecular features such as MYCN amplification, and/or response to chemotherapy.

项与 Hu14.18K322A 相关的新闻（医药）

2024-12-12

·GlobeNewswire-Health Care

Essential Pharma announces €900 million recapitalisation through a Gyrus Capital Continuation Vehicle led by AlpInvest and new strategic financing from Sixth Street

Essential Pharma announces €900 million recapitalisation through a Gyrus Capital Continuation Vehicle led by AlpInvest and new strategic financing from Sixth Street Provides significant resources to build on diversified portfolio of established and rare disease medicines Egham, UK – 12 December 2024 – Essential Pharma (“Essential” or “the Company”), an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, today announces the completion of a €900 million financing, through a Gyrus Capital single-asset Continuation Vehicle led by AlpInvest, a subsidiary of Carlyle Global Investment Solutions, and a new strategic financing facility with Sixth Street. Essential Pharma was acquired in 2019 by Gyrus Capital, who have supported the transformation of the Company into a global, high-growth specialty pharma group with significant development opportunities. The transaction will enable Essential to deploy additional capital to build on its diversified portfolio and late-stage pipeline across established and rare disease medicines. This will be achieved through its successful acquisition and development strategy under the leadership of CEO, Emma Johnson. This additional capital will support Essential’s mission to ensure access to essential medicines for patients across new and existing markets. Since her appointment in 2023, Emma has driven the Company’s expansion into rare diseases, with the addition of marketed product Colobreathe® and Hu14.18, an immunotherapy in late-stage clinical development for the treatment of high-risk neuroblastoma. Following the transaction, Lee Morley, appointed as Non-Executive Director to the Board in 2023, will assume the role of Chairman of Essential Pharma, succeeding Dr Patrick Vink. Lee has more than 30 years’ experience in the biopharmaceutical industry, with extensive knowledge of commercialisation, pricing, reimbursement and product launch strategy. He was a co-founder and CEO at EUSA Pharma before the company’s €750 million acquisition by Recordati (BIT: REC) in 2022. During his time at EUSA Pharma, he led the company’s transition from specialty pharma to oncology and rare disease, driving sales from €20 million to €150 million. Emma Johnson, CEO of Essential Pharma, commented: “This transaction provides us with substantial additional firepower, strengthening our ability to deliver essential medicines to patients who need them most. By moving into new geographical markets and building on our diversified portfolio and late-stage pipeline across our key therapeutic areas, we can expand our reach to help underserved patient populations across the globe. We are excited to continue our relationship with Gyrus Capital as we execute our strategy to become a leading, global specialty pharma group with a growing rare disease presence, where patient needs are often most acute. As we transition to our new ownership, I’d also like to thank Patrick for his significant contributions as Chairman and welcome Lee as he steps into the role.” Dr Robert Watson, Managing Partner at Gyrus Capital, said: “This is a landmark investment for Essential and for Gyrus Capital. We are delighted to partner with AlpInvest, Stepstone, Sixth Street and other significant private capital institutions, who believe in our shared vision of building an exceptional specialty pharma company, and bringing critical medical products to patients across the globe.” Sixth Street, a leading global investment firm with deep experience supporting biotech companies across all stages of growth, is providing a new strategic financing facility consisting of €300 million in structured equity and growth debt. Jeff Pootoolal, Partner at Sixth Street who will join the board of Essential Pharma, said: “Essential Pharma has assembled a leading team and platform in its pursuit of providing patients around the world with critical medicines. We are excited to support Emma and Essential’s leadership as they continue to execute and expand on their mission.” About Essential Pharma Essential Pharma is an international specialty pharmaceutical group dedicated to maintaining access to clinically differentiated, niche, branded medicines across multiple therapeutic areas. The group has been an important and valued partner to healthcare providers for over 20 years by giving underserved patient populations access to medicines that otherwise might not be available, and addressing clinical unmet needs. Essential Pharma operates globally in more than 70 countries, supplying a portfolio of products with a focus on the central nervous system (CNS), gastroenterology, ophthalmology, and rare disease. The group’s growth strategy is centred on portfolio optimisation and a targeted M&A approach to acquire commercial and late-clinical stage assets in the four therapeutic areas of focus. It is a trusted partner to multiple pharma companies of all sizes, with a proven history of integrating assets and managing complex technology transfers seamlessly while ensuring continuous supply to patients. For more information, please visit essentialpharmagroup.com About Gyrus Capital Gyrus Capital is a European investment firm dedicated to transformational investments in the healthcare and sustainability sectors. Based in Geneva, Switzerland, Gyrus invests in businesses that address the structural needs of society and the environment and are positioned for long-term sustainable growth. The firm focuses on complex transactions, particularly corporate carve-outs in the €50 million to €500 million range. A renowned group of experienced partners and industry experts supports Gyrus’s active investment and value-creation approach, working closely with entrepreneurs and managers. To learn more, please visit www.gyruscapital.com About Sixth Street Sixth Street is a global investment firm with over $80 billion in assets under management and committed capital. Sixth Street uses its long-term flexible capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. Sixth Street Healthcare and Life Sciences finances the development and commercialization of innovative therapeutics and invests in healthcare technology companies across all stages of growth. Investments in the sector include Apellis Pharmaceuticals, Arrowhead Pharmaceuticals, Arsenal Biosciences, Biohaven, Blueprint Medicines, Caris Life Sciences, Chroma Medicine, ConcertAI, Datavant, Immunogen, Ironwood, and Mammoth Biosciences, among many others. Founded in 2009, Sixth Street has more than 650 team members including over 250 investment professionals operating around the world. For more information, visit www.sixthstreet.com, or follow Sixth Street on LinkedIn. CONTACTS Essential Pharma Emma Johnson, CEO Tel: +44(0)1784 477 167 Email: info@essentialpharmaceuticals.com ICR Healthcare Tracy Cheung/Sukaina Virji/Isabelle Abdou Tel: +44 (0) 20 3709 5700 Email: Essentialpharma@icrhealthcare.com

高管变更并购

2024-06-12

·GlobeNewswire-Health Care

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma 11 June, 2024 – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, today announced its rare disease business has signed a strategic agreement with AGC Biologics. As a leading global biopharmaceutical contract development and manufacturing organisation (CDMO), AGC Biologics will produce Hu1418K322A (Hu14.18), a humanised monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB). Under the agreement, AGC Biologics will support the process development, scale-up and manufacturing as Essential Pharma plans to commence clinical activities and ongoing regulatory agency interactions over the coming months. Simon Ball, Vice President of the rare disease business at Essential Pharma, commented: "This partnership is a tremendous milestone in the development of Hu14.18 and its path to commercialization. The prospect of building an inventory of Hu14.18 is very exciting. Ahead of us is a period of intense regulatory agency interaction, which will take place alongside late-stage clinical development, and we are a step closer to providing this high-potential antibody to a patient group that is desperately in need of more optimal treatments and better outcomes.” "AGC Biologics is a global leader in contract antibody development and manufacturing,” stated Emma Johnson, CEO of Essential Pharma. “This partnership will help us to accelerate the late-stage development of Hu14.18, which shows therapeutic promise for high-risk neuroblastoma patients, the majority of whom are young children. We look forward to working closely with AGC to deliver this potentially transformative therapy in an area of significant unmet need.” Christoph Winterhalter, CBO at AGC Biologics, said: “We are very pleased that Essential Pharma has chosen us to manufacture this innovative therapy. Our Copenhagen site has the expertise and experience in therapeutic antibodies to accelerate the late-stage development and manufacturing of Hu14.18. We look forward to partnering with Essential Pharma and working together to ensure the product meets the high level of quality, yield and all data packages needed to successfully master future clinical trials and regulatory agency submissions to supply patients across the globe with this life-saving product.” Essential Pharma acquired Renaissance Pharma in April 2024 and is now responsible for the development of Hu14.18. A Phase II trial incorporating Hu14.18 into first-line therapy, and additionally within post-consolidation therapy for HRNB patients, demonstrated positive patient outcomes with 3-year event-free survival (EFS) of 73.7% and overall survival (OS) of 86.0%. Data from this study were published in the Journal of Clinical Oncology in December 2021 and are approaching five-year OS readouts.1 Essential Pharma is an international specialty pharmaceutical group dedicated to maintaining access to clinically differentiated, niche medicines in small patient populations. The group has been an important and valued partner to healthcare providers for over 20 years by giving underserved patient populations access to medicines that otherwise might not be available, and addressing clinical unmet needs. Essential Pharma operates globally in more than 70 countries, supplying a portfolio of products with a focus on the central nervous system (CNS), gastroenterology, ophthalmology, and rare disease. The group’s growth strategy is centred on portfolio optimisation and a targeted M&A approach to acquire commercial and late-clinical stage assets in the four therapeutic areas of focus. It is a trusted partner to pharma companies of all sizes, with a proven history of integrating assets and managing complex technology transfers seamlessly while ensuring continuous and sustainable supply to patients. Essential Pharma is backed by Gyrus Capital, an investment firm dedicated to transformational investments in sectors with long-term sustainable growth, including healthcare. AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. We currently employ more than 2,500 Team Members worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is a part of AGC Inc.’s Life Science Company. The Life Science company runs ten different facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. 1 Furman WL, McCarville B, Shulkin BL, Davidoff A, Krasin M, Hsu CW, et al. Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. Journal of Clinical Oncology [Internet]. 2022 Feb 1;40(4):335–44. Available from: http://dx.doi.org.libproxy1.nus.edu.sg/10.1200/jco.21.01375 The content above comes from the network. if any infringement, please contact us to modify.

临床结果免疫疗法

2024-04-18

·Pharmaceutical Technology

Essential Pharma acquires Reminyl from Janssen Pharmaceutica

Reminyl is intended to treat mild to moderately severe dementia of the Alzheimer type. Credit: Hryshchyshen Serhii / Shutterstock.com. Speciality pharmaceutical group Essential Pharma has concluded the acquisition of Reminyl oral capsules from Johnson & Johnson company Janssen Pharmaceutica. The strategic move enhances Essential Pharma’s portfolio of central nervous system (CNS) medicines and expands its global footprint, particularly in Asia-Pacific. A cholinesterase inhibitor, Reminyl is an established CNS drug for mild to moderately severe dementia of the Alzheimer type. Essential Pharma will now hold rights to Reminyl in the European Economic Area, South Korea, Thailand and all other existing markets for this product. The deal excludes the UK and Ireland, Japan and Latin America. See Also: Inaticabtagene autoleucel by Juventas Cell Therapy for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval Ulixacaltamide hydrochloride by Praxis Precision Medicines for Essential Tremor: Likelihood of Approval The acquisition aligns with Essential Pharma’s focus on CNS, gastroenterology, ophthalmology and rare diseases. Essential operates in more than 70 countries and is supported by healthcare investment firm Gyrus Capital. Essential CEO Emma Johnson stated: “Our acquisition of rights to Reminyl in these markets will ensure Alzheimer’s patients and caregivers in those regions have continued access to this vital medicine. “The acquisition represents a significant and synergistic addition to our concentrated portfolio of CNS products, further expanding our global presence and solidifying our position as a leading speciality pharma group.” The latest development comes after Essential Pharma acquired clinical-stage pharmaceutical company Renaissance Pharma for an undisclosed sum in April 2024. Renaissance develops treatments for paediatric rare diseases, with its lead asset, Hu14.18K322A, currently being analysed in a Phase II clinical trial to treat high-risk neuroblastoma.

临床2期细胞疗法并购临床1期

100 项与 Hu14.18K322A 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高风险神经母细胞瘤	临床2期	美国	St. Jude Children's Research Hospital, Inc.	2013-07-05
淋巴瘤	药物发现	美国	St. Jude Children's Research Hospital, Inc.	2014-10-10
尤文肉瘤	药物发现	美国	St. Jude Children's Research Hospital, Inc.	2008-10-08
黑色素瘤	药物发现	美国	St. Jude Children's Research Hospital, Inc.	2008-10-08
转移性骨肉瘤	药物发现	美国	St. Jude Children's Research Hospital, Inc.	2008-10-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01857934 (CTgov)	临床2期	神经母细胞瘤 \| 高风险神经母细胞瘤	153	hu14.18K322A (NB2012 Therapy (Including Induction, Consolidation, and MRD) Antibody (hu14.18K322A))	衊製憲蓋衊廠窪醖膚願(構構範蓋製齋獵鹹廠壓) = 顧願醖鏇餘鏇醖構鏇繭醖鹹鬱鹹繭鹹窪鏇觸鑰 (鏇築壓齋壓構壓餘繭衊, 築願襯鑰醖築繭鏇構齋 ~ 鹹廠醖憲築廠鹽顧網鹹)	-	2023-02-24
NCT01857934 (CTgov)	临床2期	神经母细胞瘤 \| 高风险神经母细胞瘤	153	NB2012+hu14.18K322A (NB2012 Therapy (Including Induction, Consolidation, and MRD) Plus Antibody (hu14.18K322A))	(夢艱鏇憲觸願選壓選餘) = 憲積鬱繭鏇醖鏇淵鬱鏇選衊構願範壓繭壓觸獵 (選淵網觸齋網膚廠餘繭, 衊窪顧淵醖獵鏇網齋鏇 ~ 願觸願鬱構選糧醖淵範) 更多	-	2023-02-24
NCT01857934 (Pubmed \| J Clin Oncol)	临床2期	高风险神经母细胞瘤	-	hu14.18K322A	範糧繭艱築壓糧構鏇鏇(膚築繭鹹艱齋窪選願鏇) = 夢襯繭齋膚觸醖鑰遞窪鏇膚鑰鹽餘觸夢範獵膚 (膚鹹蓋艱積遞範廠願齋, 60.0 ~ 83.4) 更多	积极	2022-02-01
NCT01857934 (Pubmed \| Clin Cancer Res) 人工标引	临床2期	神经母细胞瘤一线	42	Chemotherapy+hu14.18K322A	(繭鹽築蓋齋築廠構範顧) = 廠醖鏇築簾醖艱構窪窪膚夢鏇壓鹹鹹鑰鹹襯築 (網網簾醖選衊遞簾艱襯, 70.9 ~ 93.3) 更多	积极	2019-11-01
SITC2017	临床1期	anti-therapeutic antibodies	38	hu14.18K322A	遞鹽築壓簾餘憲簾窪襯(選糧鬱簾遞鹽鬱衊築餘) = 顧膚淵壓廠構鹹鬱壓網鹽獵願鏇網窪蓋衊夢壓 (選觸夢鑰淵顧艱願衊鹽 )	积极	2017-11-07
NCT01576692 (Pubmed \| Clin Cancer Res) 人工标引	临床1期	复发性神经母细胞瘤 \| 难治性神经母细胞瘤	13	Chemotherapy+hu14.18K322A+NK cells	(獵醖艱憲獵憲襯衊齋鑰) = One patient developed an unacceptable toxicity (grade 4 thrombocytopenia >35 days). Four patients discontinued treatment for adverse events (hu14.18K322A allergic reaction, viral infection, surgical death, second malignancy). Common toxicities included grade 3/4 myelosuppression (13/13 patients) and grade 1/2 pain (13/13 patients). 廠糧鹽膚鹹艱鬱憲選襯 (積構遞積醖網遞醖衊鏇 )	积极	2017-11-01